AIIMS Delhi Starts Screening Children Between 2 & 18 Years for Bharat Biotech’s Covid-19 Vaccine, Covaxin, Trials

Total Views |

AIIMS_1  H x W:
The All India Institute of Medical Sciences (AIIMS), Delhi, has started screening children for clinical trials of indigenous home-grown Covid-19 vaccine, Bharat Biotech's Covaxin, sources said.
AIIMS, Delhi will be starting clinical trials after AIIMS Patna which started the trials recently on children aged between 2 and 18 years.
After getting permission from the Drugs Controller General of India (DCGI), AIIMS, Delhi is now starting the screening for clinical trials before starting the trials.
To grant the permission of trials, DCGI's approval was followed by a recommendation on May 12 by a Subject Expert Committee (SEC).
The government is leaving no stone unturned to prepare for the third wave if it comes. Currently, only people above 18 years are being inoculated in the country.
The government has already administered more than 23.5 crore doses in the country.